제약 산업의 시야를 넓히는 mRNA 기술

This report provides a comprehensive analysis of the evolving landscape of mRNA technologies in pharmaceutical development, with a focus on their impact beyond COVID-19 vaccines. It examines the scientific and commercial progress of mRNA-based vaccines and therapeutics, including advances in delivery platforms, manufacturing and the emergence of novel modalities, such as circular RNA and self-amplifying RNA. The report also highlights how AI, nanotechnology and gene editing are driving innovation in mRNA design and application, while assessing the regulatory and market forces shaping the sector. Gain insights into the advantages and limitations of different mRNA formats, the challenges of targeted delivery and immunogenicity and the future potential of mRNA technologies in areas such as personalised cancer vaccines, rare diseases and next-generation gene editing therapies.

Key Questions Answered:

• 1. How has mRNA technology impacted the development of vaccines and therapeutics?
• 2. What are the advantages and disadvantages of different mRNA modalities compared to linear mRNA?
• 3. What challenges must be addressed to fully realise the potential of mRNA technologies?
• 4. How might novel technologies like circular RNA, self-amplifying RNA, base editing and CRISPR influence the mRNA landscape?
• 5. What are the latest trends in mRNA-based vaccine and therapeutic development?
• 6. What future opportunities exist for applying mRNA technology to a broader range of diseases?
• 7. How are advances in manufacturing and delivery improving mRNA product quality and accessibility?
• 8. What regulatory considerations are shaping the development and commercialisation of mRNA-based products?
• 9. How are disruptive technologies, such as AI and machine learning, accelerating mRNA innovation?
• 10. What are the key market drivers and investment trends in the mRNA therapeutics sector?

Key Companies:

Partial List of Participating Experts:

• Executive Director of Biosafety Services, Advarra, US
• CEO, Circio Holding ASA, Norway
• CSO and co-founder, Sensible Biotechnologies, UK
• CEO and co-founder, Sensible Biotechnologies, UK

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.